IRCT20200720048140N1 IRCT 2020-07-27 Kashan University of Medical Sciences The prevalence of antibiotic resistance in pediatrices (3-15 years old) with purulent sore throat The prevalence of antibiotic resistance in pediatrices (3-15 years old) with streptococcal pharyngitis 2018-05-22 anticipated 310 Complete https://irct.ir/trial/49758 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 2 Streptococcal pharyngitis. Intervention 1: Patients with positive culture, ie definite cases of streptococcal pharyngitis; Divided into 4 groups Intervention group 1: (Penicillin group) In this group of patients weighing less than 27 kg one dose of penicillin 6.3.3 muscle ampoule and Patients weighing more than 27 kg one dose of penicillin muscle ampoule 1.2 million units and 48 hours later re-culture and antibiogram were performed to evaluate antibiotic resistance.(Tri-Pen vial 6.3.3 and Benzapen vial 1,200,000 units). Intervention 2: Intervention group2 : azithromycin group In this group, patients treated with suspension or azithromycin tablets with a dose of 12 mg per kg, single daily dose for 5 days.Then re-culture and antibiogram were performed to evaluate antibiotic resistance.(Azithromycin suspension 100 and 200 mg and tablets 250 and 500 mg from Farabi company). Intervention 3: Intervention group3: clindamycin group In this group, patients were treated with clindamycin at a dose of 7 mg per kg per dose, every 8 hours, for 10 days.Then re-culture and antibiogram were performed to evaluate antibiotic resistance.(Clindafarm capsules 150 and 300 mg). Intervention 4: Intervention group4: amoxicilin group In this group, patients were treated with amoxicillin at a dose of 50 mg per kg daily, divided every 8 hours, for 10 days.Then re-culture and antibiogram were performed to evaluate antibiotic resistance.(Amoxicillin suspension 125 and 250 mg and capsules 250 and 500 mg from Farabi company). No - There is not a plan to make this available Justification or reason for not sharing IPD is Non-disclosure of patient information